Showing 6181-6190 of 9846 results for "".
- With New Funding, Turn Therapeutics Will Launch Phase 4 Study of AD Drughttps://practicaldermatology.com/news/with-new-funding-turn-therapeutics-will-launch-phase-4-study-of-ad-drug/2460162/Turn Therapeutics has closed its fully-subscribed series B financing. The capital raised will fund a large-scale, pre-launch, phase 4 trial for AtopX Eczema Emulsion, with enrollment scheduled to begin in Q1 2020. The series B financing will also support advancement of additional i
- Positive Top Line Results from Second Phase 3 Study of Abrocitinib for Atopic Dermatitishttps://practicaldermatology.com/news/positive-top-line-results-from-second-phase-3-study-of-abrocitinib-for-atopic-dermatitis-1/2460159/Pfizer Inc. shared positive top-line results from a second Phase 3 pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis (AD). This is the second monotherap
- Study: Recell System Plus Dermabrasion Speeds Acne Scar Healinghttps://practicaldermatology.com/news/study-recell-system-plus-dermabrasion-speeds-acne-scar-healing/2460154/When combined with dermabrasion, the RECELL Autologous Cell Harvesting Device speeds the healing of facial acne scars, according to a study in Aesthetic Plastic Surgery. The RECELL System uses a small
- Positive Results for Aclaris Therapeutics’ A-101 45% Topical Solution in Pivotal Phase 3 Trial for the Treatment of Wartshttps://practicaldermatology.com/news/positive-results-for-aclaris-therapeutics-a-101-45-topical-solution-in-pivotal-phase-3-trial-for-the-treatment-of-warts/2460151/Aclaris Therapeutics, Inc., shared positive results from its Phase 3 clinical trial, THWART-2 (WART-302), of A-101 45% Topical Solution, an investigational new drug for the treatment of common warts (verruca vulgaris). A-101 45% Topical Solution met the
- Study: Long-Term Use of Brodalumab Is Safe, Effectivehttps://practicaldermatology.com/news/study-long-term-use-of-brodalumab-is-safe-effective/2460150/Long-term use of brodalumab (SILIQ) improved skin clearance and quality of life in patients with moderate-to-severe psoriasis, according to a new study in the American Journal of Clinical Dermatology. Ov
- With Fibrocell Acquisition, Castle Creek Expands Late-Stage EB Pipelinehttps://practicaldermatology.com/news/with-fibrocell-acquisition-castle-creek-expands-late-stage-eb-pipeline/2460149/Castle Creek Pharmaceutical Holdings, Inc. acquired Fibrocell Science, Inc., a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases. With the resources of CCP Holdings’ subsidiary,
- Increased Adherence, Symptom Improvement Seen When Psoriasis Patients Switch to IL-17 Blockershttps://practicaldermatology.com/news/increased-adherence-symptom-improvement-seen-when-psoriasis-patients-switch-to-il-17-blockers/2460147/New data points to increased adherence and improvement in symptoms for psoriasis patients who switch to interleukin-17 inhibitors. The study, which was conducted with Walgreens, a parent company of AllianceRx Walgreens Prime, was presented at the National Association of Specialty Pharma
- SENTÉ Partners with Scientis to Introduce Cysperahttps://practicaldermatology.com/news/sente-partners-with-scientis-to-introduce-cyspera/2460146/SENTÉ is partnering with Scientis, a Swiss dermatology company dedicated to developing novel dermo-cosmetic solutions to address skin pigmentation concerns, to introduce Cyspera®. Cyspera, a physician exclusive skincare product, is a novel intensive
- Innovations In Skin Of Color Dermatology Award Presented to Dr. Andrew F. Alexishttps://practicaldermatology.com/news/innovations-in-skin-of-color-dermatology-award-presented-to-dr-andrew-f-alexis/2460140/The Journal of Drugs in Dermatology (JDD) presented dermatologist Andrew F. Alexis, MD, MPH, with the Innovations in Skin of Color Dermatology Award at Skin of Color Update, formerly Skin of Color Seminar Series, held September 7 and 8 in New York. The award recognizes individuals who ha
- ASDS 2018 Survey: Skin Cancer Treatments and Cosmetic Procedures are on the Risehttps://practicaldermatology.com/news/asds-2018-survey-skin-cancer-treatments-and-cosmetic-procedures-are-on-the-rise/2460133/American Society for Dermatologic Surgery (ASDS) member dermatologists performed more than 12.5 million medical and cosmetic procedures in 2018 – 7.5 percent more than 2017 and a 60 percent increase since 2012, according to the 2018 ASDS